Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Japanese encephalitis chimeric virus vaccine (JE-CV)
Japanese encephalitis chimeric virus vaccine · 1 trial · 2 indications
Immunogenicity was assessed by the JE-CV virus and the SA14-14-2 virus 50% plaque reduction neutralization test (PRNT50). Japanese Encephalitis seroconversion was defined as a pre-vaccination titer \<10 1/dil and post-vaccination titer ≥ 10 1/dil; or a pre-vaccination titer ≥ 10 1/dil and a 4-fold increase from pre- to post-vaccination.
| Arm | Type | Description |
|---|---|---|
| JE-CV Group | EXPERIMENTAL | Participants will receive one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) |
| SA14-14-2 vaccine Group | ACTIVE_COMPARATOR | Participants will receive one dose of Japanese encephalitis live vaccine, SA14-14-2 vaccine. (CD.JEVAX®) |
| Name | Type | Description |
|---|---|---|
| Japanese encephalitis chimeric virus vaccine (JE-CV) | BIOLOGICAL | 0.5 mL, Subcutaneous |
| Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®) | BIOLOGICAL | 0.5 mL, Subcutaneous |
Inclusion Criteria : * Aged 9 to 18 months on the day of inclusion * In good general health, without significant medical history * Provision of informed consent form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by loca...
The Japanese encephalitis chimeric virus vaccine is a vaccine intended to prevent Japanese encephalitis, a viral infection of the brain. It is being studied in infants and toddlers, with encephalitis and Japanese encephalitis listed as the conditions in its clinical program. It is an investigational product rather than a marketed therapy.
Sanofi is the developer of the Japanese encephalitis chimeric virus vaccine. Sanofi trades on the New York Stock Exchange under the ticker SNY. The company is responsible for the clinical development program for this vaccine candidate.
The Japanese encephalitis chimeric virus vaccine is in Phase 3 development. Its single recorded Phase 3 trial has been completed, and no trials are currently listed as active. The vaccine remains an investigational candidate and is not described as approved.
One Phase 3 trial has studied the Japanese encephalitis chimeric virus vaccine: NCT01092507, titled A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers. It was completed, enrolled 300 participants in Thailand, and was randomized, double blind, and active controlled.
Yes, JE-CV is the abbreviated name for the Japanese encephalitis chimeric virus vaccine. Both names refer to the same Sanofi vaccine candidate. Readers searching for JE-CV will find the same Phase 3 program, including the completed trial NCT01092507 in infants and toddlers.
The Japanese encephalitis chimeric virus vaccine was studied in healthy infants and toddlers from 9 months of age, with both sexes eligible. The completed Phase 3 trial NCT01092507 enrolled 300 participants in Thailand and compared the vaccine with the SA14-14-2 vaccine in an active-controlled design.